2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.

Nerve growth factor receptor (NGFR), a member of kinase protein, is emerging as an important target for Glioblastoma (GBM) treatment. Overexpression of NGFR is observed in many metastatic cancers including GBM, promoting tumor migration and invasion. Hydrazones have been reported to effectively interact with receptor tyrosine kinases (RTKs).

Decane-1,2-diol derivatives as potential antitumor agents for the treatment of glioblastoma.

Glioblastoma remains the most common and aggressive type of malignant brain tumor among adults thus, considerable attention has been given to discovery of novel anti-tumor drugs for its treatment. This study reports the synthesis of a series of twelve novel decane-1,2-diol derivatives and evaluation of its anti-tumor activity in mammalian glioblastoma cell lines, U87 and LN229. Starting from decane-1,2-diol, several derivatives were prepared using a diversity oriented synthesis approach through which a small library composed of esters, silyl ethers, sulfonates, sulfites, sulfates, ketals, and phosphonates was built.

Management of acute vertigo with betahistine.

This open, prospective study was carried out in 29 outpatients of vertigo with Betahistine treatment at a dose of 16 mg three times daily far a maximum treatment period of 6 weeks or earlier until remission of vertigo attacks. The evaluations were carried out based on three parameters such as frequency, duration, and severity of vertigo attacks. Betahistino showed a significant improvement in the three parameters of frequency, duration and severity of vertigo attacks.